The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
Open accessAbstract
BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known. METHODS: We conducted a randomized, double-blind, double-dummy trial comparing two once-daily regimens of edoxaban with warfarin in 21,105 patients with moderate-to-high-risk atrial fibrillation (median follow-up, 2.8 years). The primary efficacy end point was stroke or systemic embolism. Each edoxaban regimen was tested for noninferiority to warfarin during the treatment period. The principal safety end point was major bleeding. RESULTS: The annualized rate of the primary end point during treatment was 1.50% with warfarin (median time in the therapeutic range, 68.4%), as compared with 1.18% with high-dose edoxaban (hazard ratio, 0.79; 97.5% confidence interval [CI], 0.63 to 0.99; P<0.001 for noninferiority) and 1.61% with low-dose edoxaban (hazard ratio, 1.07; 97.5% CI, 0.87 to 1.31; P=0.005 for noninferiority). In the intention-to-treat analysis, there was a trend favoring high-dose edoxaban versus warfarin (hazard ratio, 0.87; 97.5% CI, 0.73 to 1.04; P=0.08) and an unfavorable trend with low-dose edoxaban versus warfarin (hazard ratio, 1.13; 97.5% CI, 0.96 to 1.34; P=0.10). The annualized rate of major bleeding was 3.43% with warfarin versus 2.75% with high-dose edoxaban (hazard ratio, 0.80; 95% CI, 0.71 to 0.91; P<0.001) and 1.61% with low-dose edoxaban (hazard ratio, 0.47; 95% CI, 0.41 to 0.55; P<0.001). The corresponding annualized rates of death from cardiovascular causes were 3.17% versus 2.74% (hazard ratio, 0.86; 95% CI, 0.77 to 0.97; P=0.01), and 2.71% (hazard ratio, 0.85; 95% CI, 0.76 to 0.96; P=0.008), and the corresponding rates of the key secondary end point (a composite of stroke, systemic embolism, or death from cardiovascular causes) were 4.43% versus 3.85% (hazard ratio, 0.87; 95% CI, 0.78 to 0.96; P=0.005), and 4.23% (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P=0.32). CONCLUSIONS: Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes. (Funded by Daiichi Sankyo Pharma Development; ENGAGE AF-TIMI 48 ClinicalTrials.gov number, NCT00781391.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Edoxaban 60 mg once daily was non-inferior to warfarin (primary outcome, HR 0.87; 97.5% CI 0.73-1.04;P = 0.08).”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [321]
In the citing paper
“while edoxaban 30 mg once daily was non-inferior to warfarin for prevention of stroke and systemic embolism but significantly reduced major bleeding events by 53%.”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [321]
In the citing paper
“In an on-treatment analysis, edoxaban 60 mg once daily significantly reduced stroke or systemic embolism by 21% and significantly reduced major bleeding events by 20% compared with warfarin”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [321]
In the citing paper
“Renal clearance”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [321]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Self-citationApixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Schulman, S., & Kearon, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,025
Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001) · JAMA · doi:10.1001/jama.285.22.2864 · Cited by 4,832
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
Schulman, S., Angerås, U., Bergqvist, D., ERIKSSON, B., Lassen, M. R., & FISHER, W. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,761
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,070
The prevention and treatment of missing data in clinical trials
Little, R. J., D'Agostino, R., Cohen, M. L., Dickersin, K., Emerson, S. S., Farrar, J. T., Frangakis, C., Hogan, J. W., Molenberghs, G., Murphy, S. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmsr1203730 · Cited by 1,884
Self-citationEdoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
The Hokusai-VTE Investigators (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306638 · Cited by 1,869
Flagged first, then by citations
Research works printed but not linked: 1
- Grip LT, 2013, Hot Topics Cardiol, 31, 7
Cited by
Sorted by citations
Items 601–700 of 1,005
Atrial Fibrillation and Heart Failure: Update 2015
Thihalolipavan, S., & Morin, D. P. (2015) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2015.07.004 · Cited by 54
Minimizing the Risk of Bleeding with NOACs in the Elderly
Kundu, A., Sardar, P., Chatterjee, S., Aronow, W. S., Owan, T., & Ryan, J. J. (2016) · Drugs & Aging · doi:10.1007/s40266-016-0376-z · Cited by 52
Patient values and preferences for antithrombotic therapy in atrial fibrillation
Loewen, P. S., Ji, T. A., Kapanen, A. I., & McClean, A. R. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-10-0787 · Cited by 53
Mitchell, A., Watson, M. C., Welsh, T. J., & McGrogan, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8040554 · Cited by 52
Xu, Y., & Siegal, D. M. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15466 · Cited by 54
Shiga, T., Naganuma, M., Nagao, T., Maruyama, K., Suzuki, A., Murasaki, K., & Hagiwara, N. (2015) · Journal of Arrhythmia · doi:10.1016/j.joa.2015.04.004 · Cited by 53
Weinberg, E. M., Palecki, J., & Reddy, K. R. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1679934 · Cited by 52
Wetmore, J. B., Weinhandl, E. D., Yan, H., Reyes, J. L., Herzog, C. A., & Roetker, N. S. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2022.03.007 · Cited by 52
Bhatia, K., Ladd, L., Carr, K., Napoli, M. D., Saver, J. L., McCullough, L. D., Farahabadi, M. H., Alsbrook, D. L., Hinduja, A., Ortiz-Garcia, J., et al. (2023) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-023-01266-2 · Cited by 57
Effect of Oral Anticoagulants in Atrial Fibrillation Patients with Polypharmacy: A Meta-analysis
Zheng, Y., Li, S., Liu, X., Lip, G. Y. H., Guo, L., & Zhu, W. (2023) · Thrombosis and Haemostasis · doi:10.1055/s-0043-1770724 · Cited by 52
Residual Risk of Recurrent Stroke Despite Anticoagulation in Patients With Atrial Fibrillation
McCabe, J. J., Cheung, Y., Foley, M., Brennan, S. O., Buckley, J., Camps‐Renom, P., Cassidy, T., Collins, R., Dolan, E., Große, G. M., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.1337 · Cited by 52
Atrial fibrillation in patients with diabetes: molecular mechanisms and therapeutic perspectives.
Sensi, F. D., Potter, T. J. R. D., Cresti, A., Severi, S., & BREITHARDT, G. E. (2015) · PubMed Central · doi:10.3978/j.issn.2223-3652.2015.06.03 · Cited by 52
Profiles of direct oral anticoagulants and clinical usage—dosage and dose regimen differences
Ieko, M., Naitoh, S., Yoshida, M., & Takahashi, N. (2016) · Journal of Intensive Care · doi:10.1186/s40560-016-0144-5 · Cited by 52
Burr, N. E., Lummis, K., Sood, R., Kane, J. S., & Subramanian, V. (2016) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(16)30162-5 · Cited by 55
Direct oral anticoagulant considerations in solid organ transplantation: A review
Salerno, D. M., Tsapepas, D. S., Papachristos, A., Chang, J., Martin, S. T., Hardy, M. A., & McKeen, J. T. (2016) · Clinical Transplantation · doi:10.1111/ctr.12873 · Cited by 55
Health literacy and warfarin therapy at two anticoagulation clinics in Brazil
Martins, M. A. P., da Costa, J. M., Mambrini, J. V. D. M., Ribeiro, A. L. P., Benjamin, E. J., Brant, L. C. C., Paasche‐Orlow, M. K., & Magnani, J. W. (2017) · Heart · doi:10.1136/heartjnl-2016-310699 · Cited by 52
Impact of Renal Function on Outcomes With Edoxaban in Real-World Patients With Atrial Fibrillation
Yu, H. T., Yang, P., Kim, T., Jang, E., Kim, D., Uhm, J., Kim, J., Pak, H., Lee, M., Lip, G. Y. H., et al. (2018) · Stroke · doi:10.1161/strokeaha.118.021387 · Cited by 52
Goto, S., Goto, S., Pieper, K. S., Bassand, J., Camm, A. J., Fitzmaurice, D. A., Goldhaber, S. Z., Haas, S., Parkhomenko, A. N., Oto, A., et al. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz076 · Cited by 52
Xian, Y., Zhang, S., Inohara, T., Grau‐Sepulveda, M. V., Matsouaka, R., Peterson, E. D., Piccini, J. P., Smith, E. E., Sheth, K. N., Bhatt, D. L., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.37438 · Cited by 52
Taniguchi, H., Takata, T., Takechi, M., Furukawa, A., Iwasawa, J., Kawamura, A., Taniguchi, T., & Tamura, Y. (2021) · International Heart Journal · doi:10.1536/ihj.21-094 · Cited by 52
Are the novel anticoagulants better than warfarin for patients with atrial fibrillation?
Hanley, C. M., & Kowey, P. R. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2015.01.23 · Cited by 51
Do Current Clinical Trials Meet Society’s Needs?
Pocock, S., & Gersh, B. J. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.08.008 · Cited by 51
The influence of atrial high-rate episodes on stroke and cardiovascular death: an update
Toennis, T., Bertaglia, E., Brandes, A., Dichtl, W., Fluschnik, N., de Groot, J. R., Marijon, É., Mont, L., Blomström‐Lundqvist, C., Cabanelas, N., et al. (2023) · EP Europace · doi:10.1093/europace/euad166 · Cited by 53
Oral Anticoagulation Use and Left Atrial Appendage Occlusion in LAAOS III
Connolly, S. J., Healey, J. S., Belley‐Côté, E. P., Balasubramanian, K., Paparella, D., Brady, K., Reents, W., Danner, B. C., Devereaux, P. J., Sharma, M., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.060315 · Cited by 51
Oral Anticoagulants Beyond Warfarin
Olie, R. H., Winckers, K., Rocca, B., & Cate, H. T. (2023) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-032823-122811 · Cited by 57
Metabolic syndrome, atrial fibrillation, and stroke: Tackling an emerging epidemic
Hajhosseiny, R., Matthews, G. D. K., & Lip, G. Y. H. (2015) · Heart Rhythm · doi:10.1016/j.hrthm.2015.06.038 · Cited by 53
Lin, L., Lim, W. S., Zhou, H. J., Khoo, A. L., Tan, K. T., Chew, A. P., Foo, D. C. G., Chin, J. J., & Lim, B. P. (2015) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2015.09.008 · Cited by 52
Dobesh, P. P., & Fanikos, J. R. (2015) · Drugs · doi:10.1007/s40265-015-0452-4 · Cited by 50
Oral Anticoagulant Therapy in Atrial Fibrillation Patients at High Stroke and Bleeding Risk
Potpara, T., & Lip, G. Y. H. (2015) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2015.07.003 · Cited by 52
Novel anticoagulants: general overview and practical considerations for dental practitioners
Elad, S., Marshall, J., Meyerowitz, C., & Connolly, G. (2015) · Oral Diseases · doi:10.1111/odi.12371 · Cited by 51
‘New’ direct oral anticoagulants in the perioperative setting
Breuer, G., Weiss, D., & Ringwald, J. (2014) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000100 · Cited by 51
Asian strategy for stroke prevention in atrial fibrillation
Chiang, C., Wang, K.-L., & Lin, S. (2015) · EP Europace · doi:10.1093/europace/euv231 · Cited by 51
Macha, K., Volbers, B., Bobinger, T., Kurka, N., Breuer, L., Huttner, H. B., Schwab, S., & Köhrmann, M. (2016) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2016.06.031 · Cited by 51
Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation
Fawzy, A. M., & Lip, G. Y. H. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1604686 · Cited by 51
“The four large phase III trials which have led to the licensing of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation are the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial [57], Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K A…”
BackgroundEdoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease
Qamar, A., Antman, E. M., Ruff, C. T., Nordio, F., Murphy, S. A., Grip, L. T., Greenberger, N. J., Yin, O. Q. P., Choi, Y., Lanz, H., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.04.061 · Cited by 52
Ziegler, P., Rogers, J., Ferreira, S. W., Nichols, A. J., Sarkar, S., Koehler, J. L., Warman, E. N., & Richards, M. (2015) · Cerebrovascular Diseases · doi:10.1159/000439063 · Cited by 48
Thromboembolic Prevention in Frail Elderly Patients With Atrial Fibrillation: A Practical Algorithm
Granziera, S., Cohen, A. T., Nante, G., Manzato, E., & Sergi, G. (2015) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2014.12.008 · Cited by 50
The current approach of atrial fibrillation management
Amin, A., Houmsse, A., Ishola, A., Tyler, J. D., & Houmsse, M. (2016) · Avicenna Journal of Medicine · doi:10.4103/2231-0770.173580 · Cited by 58
Why switch from warfarin to NOACs?
Verdecchia, P., Angeli, F., Aita, A., Bartolini, C., & Reboldi, G. (2016) · Internal and Emergency Medicine · doi:10.1007/s11739-016-1411-0 · Cited by 51
Kim, K., Lee, Y., Kim, T.-H., Uhm, J., Pak, H., Lee, M., & Joung, B. (2018) · Korean Circulation Journal · doi:10.4070/kcj.2017.0328 · Cited by 50
Use of direct oral anticoagulants in antiphospholipid syndrome
Cohen, H., Efthymiou, M., & Isenberg, D. A. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14017 · Cited by 69
Raccah, B. H., Perlman, A., Zwas, D. R., Hochberg-Klein, S., Masarwa, R., Muszkat, M., & Matok, I. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018771264 · Cited by 50
Overview of oral antithrombotic treatment in elderly patients with atrial fibrillation
Kato, E. T., Goto, S., & Giugliano, R. P. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.10.006 · Cited by 51
Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin
Alberts, M. J., Chen, Y.-W., Lin, J., Kogan, E., Twyman, K., & Milentijevic, D. (2019) · Stroke · doi:10.1161/strokeaha.119.025554 · Cited by 50
Wetmore, J. B., Roetker, N. S., Yan, H., Reyes, J. L., & Herzog, C. A. (2020) · Stroke · doi:10.1161/strokeaha.120.028934 · Cited by 50
Atrial Fibrillation and Stroke
Essa, H., Hill, A. M., & Lip, G. Y. H. (2021) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2020.11.003 · Cited by 53
Giugliano, R. P., Ruff, C. T., Rost, N. S., Silverman, S. B., Wiviott, S. D., Lowe, C., Deenadayalu, N., Murphy, S. A., Grip, L. T., Betcher, J., et al. (2014) · Stroke · doi:10.1161/strokeaha.114.006025 · Cited by 49
Lip, G. Y. H., Skjøth, F., Nielsen, P. B., Kjældgaard, J. N., & Larsen, T. B. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.1883 · Cited by 50
Atrial fibrillation screening with photo-plethysmography through a smartphone camera
Verbrugge, F. H., Proesmans, T., Vijgen, J. M., Müllens, W., Rivero‐Ayerza, M., Herendael, H. V., Vandervoort, P. M., & Nuyens, D. (2019) · EP Europace · doi:10.1093/europace/euz119 · Cited by 50
Huang, H., Liu, P. P., Hsu, J., Lin, S., Peng, C. C., Wang, J., & Loh, C. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz952 · Cited by 49
Direct Oral Anticoagulant Concentrations in Obese and High Body Weight Patients: A Cohort Study
Martin, A., Thomas, W. T. B., Mahir, Z., Crowley, M. P., Dowling, T., Breen, K. A., Collings, V., Moore, G. W., MacDonald, S. G., Hunt, B. J., et al. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1715834 · Cited by 49
Cools, F. J. S., Johnson, D., Camm, A. J., Bassand, J., Verheugt, F. W. A., Yang, S., Tsiatis, A. A., Fitzmaurice, D. A., Goldhaber, S. Z., Kayani, G., et al. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15415 · Cited by 51
Vinereanu, D., Stevens, S. R., Alexander, J. H., Al‐Khatib, S. M., Avezum, Á., Bahit, M. C., Granger, C. B., Lópes, R. D., Halvorsen, S., Hanna, M., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv447 · Cited by 51
Drouet, L. O., Sollier, C. B. D., Steiner, T., & Purrucker, J. C. (2016) · International Journal of Stroke · doi:10.1177/1747493016659671 · Cited by 50
G, S. K. C., Danik, S. B., Altman, R., Barrett, C. D., Lip, G. Y. H., Chatterjee, S., Roubin, G. S., Natale, A., & Danik, J. S. (2015) · Cardiology in Review · doi:10.1097/crd.0000000000000088 · Cited by 50
Edoxaban: A direct oral anticoagulant
Poulakos, M. N., Walker, J. N., Baig, U., & David, T. (2017) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp150821 · Cited by 49
Steinberg, B. A., Simon, D. N., Thomas, L. E., Ansell, J., Fonarow, G. C., Gersh, B. J., Kowey, P. R., Mahaffey, K. W., Peterson, E. D., & Piccini, J. P. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.02.015 · Cited by 49
Severity of Gastrointestinal Bleeding in Patients Treated with Direct-Acting Oral Anticoagulants
Brodie, M. M., Newman, J. C., Smith, T., & Rockey, D. C. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.11.007 · Cited by 51
The use of direct oral anticoagulants in chronic kidney disease
Parker, K., & Thachil, J. V. (2018) · British Journal of Haematology · doi:10.1111/bjh.15564 · Cited by 51
“An observational study by Graham et al (2016), comparing outcomes with dabigatran and rivaroxaban in patients with AF, found an increased risk of intracranial haemorrhage and major gastrointestinal (GI) bleeds with rivaroxaban.”
Nielsen, P. B., Skjøth, F., Søgaard, M., Kjældgaard, J. N., Lip, G. Y. H., & Larsen, T. B. (2019) · Stroke · doi:10.1161/strokeaha.118.023797 · Cited by 49
Inappropriate Dosing of Direct Oral Anticoagulants in Patients with Atrial Fibrillation
Sugrue, A. M., Sanborn, D. M., Amin, M., Farwati, M., Sridhar, H., Ahmed, A., Mehta, R. A., Siontis, K. C., Mulpuru, S. K., Deshmukh, A. J., et al. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.12.062 · Cited by 49
“The primary outcomes of interest after index DOAC prescription date were the occurrence of (1) ischemic stroke/TIA/embolism, (2) major bleeding, (3) clinically relevant non-major bleeding, and (4) any bleeding which included major, clinically relevant non-major bleeding, and minor bleeding.”
MethodJönsson, S., Simonsson, U. S. H., Miller, R., & Karlsson, M. O. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.541 · Cited by 48
Wu, T., Lv, C., Wu, L., Chen, W., Lv, M., Jiang, S., & Zhang, J. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10448-2 · Cited by 51
Komen, J. J., Pottegård, A., Mantel-Teeuwisse, A. K., Forslund, T., Hjemdahl, P., Wettermark, B., Hallas, J., Olesen, M. S., Bennie, M., Mueller, T., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac111 · Cited by 50
Secondary Ischemic Stroke Prevention
Bangad, A., Abbasi, M., & de Havenon, A. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01352-w · Cited by 60
“Additionally, edoxaban has shown non-inferiority in both low (30 mg once daily) and high (60 mg once daily) doses compared to warfarin in patients with non-valvular AF [82].”
BackgroundAnticoagulation in chronic kidney disease: current status and future perspectives
Jones, A. P., Swan, D., Lisman, T., Barnes, G. D., & Thachil, J. V. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.09.020 · Cited by 51
Marston, N., Pirruccello, J. P., Melloni, G. E. M., Kamanu, F., Bonaca, M. P., Giugliano, R. P., Scirica, B. M., Wiviott, S. D., Bhatt, D. L., Steg, P. G., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03188-z · Cited by 47
Herzog, E., Kaspereit, F., Krege, W., Doerr, B., Mueller‐Cohrs, J., Pragst, I., MORISHIMA, Y., & Dickneite, G. (2014) · Anesthesiology · doi:10.1097/aln.0000000000000520 · Cited by 48
Loffredo, L., Perri, L., & Violi, F. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2015.01.159 · Cited by 48
Barrios, V., Escobar, C., Prieto, L., Osorio, G., Polo, J., Lobos, J. M., Vargas, D., & García, N. (2015) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2015.04.017 · Cited by 48
Drug-drug interactions of non-vitamin K oral anticoagulants
Voukalis, C., Lip, G. Y. H., & Shantsila, E. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1225037 · Cited by 51
Rivaroxaban for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Active Cancer
Laube, E., Yu, A. F., Gupta, D., Miao, Y., Samedy, P., Wills, J., Harnicar, S. J., Soff, G. A., & Mantha, S. H. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.04.009 · Cited by 48
Milling, T. J., & Frontera, J. A. (2017) · PubMed · Cited by 48
Sato, T., Aizawa, Y., Fuse, K., Fujita, S., Ikeda, Y., Kitazawa, H., Takahashi, M., & Okabe, M. (2018) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2018.07.028 · Cited by 48
Nazha, B., Pandya, B., Cohen, J. L., Zhang, M., Lópes, R. D., Garcia, D. A., Sherwood, M. W., & Spyropoulos, A. C. (2018) · Circulation · doi:10.1161/circulationaha.117.031457 · Cited by 48
Zeballos-Palacios, C. L., Hargraves, I. G., Noseworthy, P. A., Branda, M. E., Kunneman, M., Burnett, B., Gionfriddo, M. R., McLeod, C. J., Gorr, H. S., Brito, J. P., et al. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.08.030 · Cited by 48
Bennaghmouch, N., de Veer, A. J. W. M., Bode, K., Mahmoodi, B. K., Dewilde, W. J. M., Lip, G. Y. H., Brueckmann, M., Kleine, E., & ten Berg, J. M. (2017) · Circulation · doi:10.1161/circulationaha.117.028513 · Cited by 48
From ancient leech to direct thrombin inhibitors and beyond: New from old
Montinari, M. R., & Minelli, S. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112878 · Cited by 47
Izzy, M. J., Fortune, B. E., Serper, M., Bhave, N. M., deLemos, A. S., Gallegos-Orozco, J. F., Guerrero-Miranda, C. Y., Hall, S. A., Harinstein, M. E., Karas, M. G., et al. (2022) · American Journal of Transplantation · doi:10.1111/ajt.17049 · Cited by 50
Jain, S. S., Mahaffey, K. W., Pieper, K. S., Shimizu, W., Potpara, T., Ruff, C. T., Kamel, H., Lewis, B. S., Cornel, J. H., Kowey, P. R., et al. (2024) · American Heart Journal · doi:10.1016/j.ahj.2024.08.011 · Cited by 51
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E. T., Sato, K., TERAMOTO, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.02.014 · Cited by 58
Stroke and Bleeding Risk in Atrial Fibrillation
Senoo, K., Lane, D. A., & Lip, G. Y. H. (2014) · Korean Circulation Journal · doi:10.4070/kcj.2014.44.5.281 · Cited by 46
Pharmacology and mechanisms of action of new oral anticoagulants
Salem, J., Sabouret, P. F., Funck‐Brentano, C., & Hulot, J. (2014) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12091 · Cited by 51
Macle, L., Cairns, J. A., Andrade, J. G., Mitchell, L. B., Nattel, S., Verma, A., Verma, A., Macle, L., Andrade, J. G., Atzema, C. L., et al. (2015) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.06.005 · Cited by 47
Lip, G. Y. H., Al‐Khatib, S. M., Cosío, F. G., Banerjee, A., Savelieva, I., Ruskin, J. N., Blendea, D. C., Nattel, S., Bono, J. D., Conroy, J., et al. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.001179 · Cited by 48
He, Y., Wong, I. C. K., Li, X., Anand, S., Leung, W. K., Siu, C., & Chan, E. W. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12911 · Cited by 47
Kodani, E., Atarashi, H., Inoue, H., Okumura, K., Yamashita, T., Origasa, H., & on behalf of the J-RHYTHM Registry Investigators (2016) · Circulation Journal · doi:10.1253/circj.cj-16-0066 · Cited by 48
Fanola, C. L., Giugliano, R. P., Ruff, C. T., Trevisan, M., Nordio, F., Mercuri, M. F., Antman, E. M., & D, E. B. M. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw565 · Cited by 47
Riccardi, A., Spinola, M. B., Minuto, P., Ghinatti, M. C., Guiddo, G., Malerba, M., & Lerza, R. (2017) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2017.03.072 · Cited by 47
Cancer, atrial fibrillation, and stroke
Fitzpatrick, T., Carrier, M., & Gal, G. L. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.05.006 · Cited by 47
Eisen, A., Ruff, C. T., D, E. B. M., Hamershock, R. A., Lewis, B. S., Hassager, C., Chao, T., Heuzey, J. Y. L., Mercuri, M. F., Rutman, H., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006035 · Cited by 48
Deitelzweig, S. B., Farmer, C., Luo, X., Li, X., Vo, L., Mardekian, J., Fahrbach, K. R., & Ashaye, A. O. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1411793 · Cited by 47
Gastrointestinal Bleeding With Edoxaban Versus Warfarin
Aisenberg, J., Chatterjee-Murphy, P., Flack, K. F., Weitz, J. I., Ruff, C. T., Nordio, F., Mercuri, M. F., Choi, Y., Antman, E. M., Braunwald, E., et al. (2018) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.117.003998 · Cited by 47
Wolfe, Z., Khan, S. U., Nasir, F., Subramanian, C. R., & Lash, B. W. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14131 · Cited by 48
Mueller, T., Alvarez‐Madrazo, S., Robertson, C., Wu, O., & Bennie, M. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13814 · Cited by 47
Shimada, K., Hasegawa, S., Nakao, S., Mukai, R., Sasaoka, S., Ueda, N., Kato, Y., Abe, J., Mōri, T., Yoshimura, T., et al. (2019) · International Journal of Medical Sciences · doi:10.7150/ijms.34629 · Cited by 47
“Randomized clinical trials (dabigatran (Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial) [1], rivaroxaban (Rivaroxaban Once-daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) trial) [2], apixa…”
BackgroundTapaskar, N., Pang, A. S., Werner, D. A., & Sengupta, N. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06248-9 · Cited by 47
Periprocedural Management of Oral Anticoagulation
Shaw, J. R., Kaplovitch, E., & Douketis, J. D. (2020) · Medical Clinics of North America · doi:10.1016/j.mcna.2020.02.005 · Cited by 47
Jakowenko, N. D., Nguyen, S. N., Ruegger, M. C., Dinh, A., Salazar, E., & Donahue, K. R. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.09.002 · Cited by 47
Hypertension Burden and the Risk of New-Onset Atrial Fibrillation
Lee, S., Park, C. S., Choi, E., Ahn, H., Han, K., Oh, S., & Lip, G. Y. H. (2021) · Hypertension · doi:10.1161/hypertensionaha.120.16659 · Cited by 47
Metadata
- Authors
- Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., Ruzyllo, W., Ruda, M., Koretsune, Y., Betcher, J., Shi, M., Grip, L. T., Patel, S. P., Patel, I., Hanyok, J. J., Mercuri, M., & Antman, E. M.
- Affiliations
- Brigham and Women's Hospital (US)
- University Hospitals Cleveland Medical Center (US)
- McMaster University (CA)
- National Medical Research Center of Cardiology (RU)
- Osaka National Hospital (JP)
- IQVIA (United States) (US)
- Daiichi Sankyo (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-11-28
- Volume
- 369
- Issue
- 22
- Pages
- 2093-2104
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2096246254
- Cited by
- 5,164
- References
- 24
- Citations by year
- 2026: 201 · 2025: 280 · 2024: 344 · 2023: 419 · 2022: 405 · 2021: 469 · 2020: 505 · 2019: 443 · 2018: 487 · 2017: 454 · 2016: 494 · 2015: 378 · 2014: 266 · 2013: 12
- FWCI
- 260.36
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- AtriCure
- Boston Scientific Corporation
- Medicines Company
- Janssen Scientific Affairs
- Bayer HealthCare
- Eisai
- St. Jude Medical
- Biosense Webster
- Janssen Pharmaceuticals
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- edoxaban, warfarin, atrial fibrillation, direct oral anticoagulants, factor Xa inhibitors, stroke and systemic embolism, major bleeding, non-inferiority, oral anticoagulation, time in therapeutic range, anticoagulant efficacy and safety, once-daily dosing
- MeSH terms
- Adult, Aged, Anticoagulants, Atrial Fibrillation, Cardiovascular Diseases, Double-Blind Method, Embolism, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Pyridines, Thiazoles, Warfarin, Stroke, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
